迷宫制药 MAZE
$34.19 +$1.66 (+5.10%)
休市 · Nov 6, 8:20 pm ET · 最新盘后价 $34.69 +1.46%
开盘$32.72
昨收$32.53
当日区间$32.42 – $35.00
成交量563.9K
市值$1.90B
市盈率（TTM）–
股息率–
股权结构与仓位
谁在持有、谁在做空，以及大资金的流向
机构持股比例106.6%-2.60 个百分点，较上季度
持仓机构数200+0 ，较上季度
内部人近期交易17次买入 / 33次卖出净卖出
空头持仓比例13.55% 占流通股回补天数 10.1 · 截至 15 Oct 2026
卖空成交量占比22.0%近5日成交量平均占比
卖空成交量占当日成交量比例
大单净流入，近20个交易日
大单买入减卖出的净额（美元）。该窗口期内：+$5.35M（12个净流入日，8个净流出日）。
按单量净流入，近20个交易日
超大单/大单近似机构级别交易；中单/小单近似散户级别交易。各档买入减卖出净额，按窗口期累计。
已披露的前五大股东合计持有39.3%的流通股。
最大股东
按投资者类型
过去6次双周报告中（31 Jul 2026至15 Oct 2026），空头持仓占流通股比例已从10.26%升至13.55%。
近期机构持仓变动
| 股东 | 类型 | 期间 | 持股变动 | 新持股比例 |
|---|---|---|---|---|
| T. Rowe Price Group, Inc. | Mutual Fund | 2026/Q3 | +2,613,857 | 4.9% |
| Braidwell LP | Hedge Fund | 2026/Q3 | +1,140,040 | 2.1% |
| BlackRock | Mutual Fund | 2026/Q3 | +932,416 | 6.3% |
| J.P. Morgan Asset Management, Inc. | Mutual Fund | 2026/Q3 | +886,028 | 1.7% |
| Farallon Capital Management, L.L.C. | Hedge Fund | 2026/Q3 | +734,814 | 2.0% |
| Logos Global Management, L.P. | Hedge Fund | 2026/Q3 | +700,000 | 3.5% |
| Marshall Wace LLP | Hedge Fund | 2026/Q3 | +603,933 | 1.6% |
| Frazier Life Sciences Management, LP | VC/PE Fund | 2026/Q3 | +465,641 | 9.1% |
| Vanguard Capital Management, LLC | Mutual Fund | 2026/Q3 | +411,504 | 3.6% |
| State Street Global Advisors | Mutual Fund | 2026/Q3 | +360,811 | 1.8% |
| Driehaus Capital Management LLC | Mutual Fund | 2026/Q3 | +318,724 | 1.7% |
| ADAR1 Capital Management, LLC | Hedge Fund | 2026/Q3 | +289,181 | 0.6% |
| Hudson Bay Capital Management LP | Hedge Fund | 2026/Q3 | +261,850 | 0.5% |
| Geode Capital Management, LLC | Mutual Fund | 2026/Q3 | +258,087 | 1.5% |
| Deep Track Capital, LP | VC/PE Fund | 2026/Q3 | +255,007 | 6.7% |
按报告期列出的机构买卖动态，变动幅度从大到小排列。
内部人交易
| 日期 | 内部人 | 职位 | 交易类型 | 股数 | 价格 | 交易后持股 |
|---|---|---|---|---|---|---|
| 30 Sep 2026 | Jason Coloma | Chief Executive Officer | Automatic Disposition | -34,501 | $27.02 | 234,367 |
| 30 Sep 2026 | Harold Bernstein | President of Research & Development and Chief Medical Officer | Derivative Exercise and Sale | -16,141 | $26.93 | – |
| 28 Sep 2026 | Atul Dandekar | Chief Strategy & Business Officer | Derivative Exercise and Sale | -7,500 | $27.06 | 32,316 |
| 3 Sep 2026 | Harold Bernstein | President of Research & Development and Chief Medical Officer | Automatic Disposition | -9,705 | $26.22 | – |
| 2 Sep 2026 | Jason Coloma | Chief Executive Officer | Open Market Disposition | -22,638 | $27.12 | 268,868 |
| 2 Sep 2026 | Atul Dandekar | Chief Strategy & Business Officer | Open Market Disposition | -6,434 | $27.12 | 32,316 |
| 2 Sep 2026 | Courtney Phillips | General Counsel | Open Market Disposition | -3,993 | $27.12 | 7,007 |
| 2 Sep 2026 | Harold Bernstein | President of Research & Development and Chief Medical Officer | Open Market Disposition | -10,295 | $27.12 | 9,705 |
| 1 Sep 2026 | Courtney Phillips | General Counsel | Intent to Sell (Form 144) | -4,144 | $26.54 | – |
| 1 Sep 2026 | Harold Bernstein | President of Research & Development and Chief Medical Officer | Intent to Sell (Form 144) | -10,685 | $26.53 | – |
| 31 Aug 2026 | Jason Coloma | Chief Executive Officer | Automatic Disposition | -34,501 | $26.31 | 291,506 |
| 31 Aug 2026 | Jason Coloma | Chief Executive Officer | Derivative Exercise and Retained | +50,000 | – | 291,506 |
| 31 Aug 2026 | Atul Dandekar | Chief Strategy & Business Officer | Derivative Exercise and Retained | +12,500 | – | 38,750 |
| 31 Aug 2026 | Courtney Phillips | General Counsel | Derivative Exercise and Retained | +11,000 | – | 11,000 |
| 31 Aug 2026 | Harold Bernstein | President of Research & Development and Chief Medical Officer | Derivative Exercise and Sale | -16,141 | $26.36 | 20,000 |
| 31 Aug 2026 | Harold Bernstein | President of Research & Development and Chief Medical Officer | Derivative Exercise and Retained | +20,000 | – | 20,000 |
| 27 Aug 2026 | Atul Dandekar | Chief Strategy & Business Officer | Derivative Exercise and Sale | -7,500 | $27.58 | 26,250 |
| 12 Aug 2026 | Paula Johnson | Director | Other Derivative Acquisition | +36,000 | $27.67 | 36,000 |
| 12 Aug 2026 | Harold Bernstein | President of Research & Development and Chief Medical Officer | Derivative Exercise and Sale | -16,142 | $27.61 | – |
| 2 Aug 2026 | Jason Coloma | Chief Executive Officer | Automatic Disposition | -34,501 | $27.09 | 276,007 |
数据来自Form 4/Form 144申报文件。负数为减持（出售、赠予或代扣税款股份），正数为增持。
空头持仓（按报告期）
| 报告日期 | 空头股数 | 占流通股比例 | 回补天数 |
|---|---|---|---|
| 15 Oct 2026 | 7,527,939 | 13.6% | 10.1 |
| 30 Sep 2026 | 6,565,330 | 11.8% | 6.1 |
| 15 Sep 2026 | 5,678,289 | 10.2% | 10.4 |
| 31 Aug 2026 | 5,918,321 | 10.7% | 16.0 |
| 14 Aug 2026 | 5,988,933 | 10.8% | 16.2 |
| 31 Jul 2026 | 5,678,545 | 10.3% | 15.9 |
暂无评论——快来第一个聊聊 MAZE。
登录后参与讨论。